| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $106,725 | 14 | 100 |
| Parison Amy | SVP, Chief Financial Officer | 0 | $0 | 5 | $6,328 | $-6,328 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 0 | $0 | 5 | $20,333 | $-20,333 |
| O'Neill Gilmore Neil | CEO | 0 | $0 | 4 | $80,064 | $-80,064 |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated …
Over the last 12 months, insiders at Editas Medicine, Inc. have bought $0 and sold $106,725 worth of Editas Medicine, Inc. stock.
On average, over the past 5 years, insiders at Editas Medicine, Inc. have bought $253,868 and sold $490,701 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 45,000 shares for transaction amount of $253,868 was made by Hopfield Jessica (director) on 2024‑05‑13.
| 2026-09-03 | Sale | O'Neill Gilmore Neil | CEO | 5,124 0.0033% | $3.04 | $15,563 | -13.64% | |
| 2026-09-03 | Sale | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 709 0.0005% | $3.04 | $2,153 | -13.64% | |
| 2026-09-03 | Sale | Parison Amy | SVP, Chief Financial Officer | 453 0.0003% | $3.04 | $1,376 | -13.64% | |
| 2026-08-03 | Sale | Parison Amy | SVP, Chief Financial Officer | 678 0.0007% | $2.58 | $1,749 | +3.77% | |
| 2026-07-28 | Sale | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 4,928 0.0051% | $2.67 | $13,158 | +4.96% | |
| 2026-06-03 | Sale | O'Neill Gilmore Neil | CEO | 15,380 0.0153% | $2.70 | $41,543 | -0.54% | |
| 2026-06-03 | Sale | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 731 0.0007% | $2.70 | $1,975 | -0.54% | |
| 2026-06-03 | Sale | Parison Amy | SVP, Chief Financial Officer | 464 0.0005% | $2.70 | $1,253 | -0.54% | |
| 2026-03-03 | Sale | O'Neill Gilmore Neil | CEO | 5,394 0.0052% | $2.02 | $10,894 | +35.78% | |
| 2026-03-03 | Sale | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 749 0.0007% | $2.02 | $1,513 | +35.78% | |
| 2026-03-03 | Sale | Parison Amy | SVP, Chief Financial Officer | 474 0.0005% | $2.02 | $957 | +35.78% | |
| 2025-12-03 | Sale | O'Neill Gilmore Neil | CEO | 5,603 0.006% | $2.15 | $12,064 | +11.81% | |
| 2025-12-03 | Sale | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 713 0.0008% | $2.15 | $1,535 | +11.81% | |
| 2025-12-03 | Sale | Parison Amy | SVP, Chief Financial Officer | 461 0.0005% | $2.15 | $993 | +11.81% | |
| 2025-09-03 | Sale | O'Neill Gilmore Neil | CEO | 5,592 0.0065% | $2.60 | $14,517 | +8.20% | |
| 2025-09-03 | Sale | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 710 0.0008% | $2.60 | $1,843 | +8.20% | |
| 2025-09-03 | Sale | Parison Amy | SVP, Chief Financial Officer | 458 0.0005% | $2.60 | $1,189 | +8.20% | |
| 2025-08-07 | Sale | Parison Amy | SVP, Chief Financial Officer | 679 0.0008% | $2.58 | $1,752 | +7.23% | |
| 2025-07-31 | Sale | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 5,121 0.0061% | $2.49 | $12,757 | +5.58% | |
| 2025-06-03 | Sale | O'Neill Gilmore Neil | CEO | 15,192 0.0172% | $1.72 | $26,196 | +40.66% |
| VIKING GLOBAL INVESTORS LP | 2729808 1.7775% | $7.1M | 1 | 0 | ||
| VIKING GLOBAL PERFORMANCE LLC | 2729808 1.7775% | $7.1M | 1 | 0 | ||
| Flynn James E | 10 percent owner | 954700 0.6216% | $2.48M | 1 | 0 | +20.25% |
| MULLEN JAMES C | CEO | 75898 0.0494% | $197,334.80 | 2 | 2 | <0.0001% |
| Hopfield Jessica | director | 67700 0.0441% | $176,020.00 | 4 | 0 | <0.0001% |
| Nikolic Boris | director | 35000 0.0228% | $91,000.00 | 1 | 0 | +77.16% |
| Cox Gerald Frank | Chief Medical Officer | 4000 0.0026% | $10,400.00 | 1 | 0 | +77.16% |
$3,887,391 | 114 | 13.01% | $433.37M | |
$31,123,523 | 108 | 6.46% | $387.86M | |
$24,384,691 | 42 | -30.27% | $396.82M | |
$2,481,409 | 33 | 201.68% | $455.48M | |
$50,191,994 | 27 | 106.80% | $466.61M |
| Increased Positions | 79 | +35.43% | 12M | +28.16% |
| Decreased Positions | 81 | -36.32% | 5M | -10.63% |
| New Positions | 32 | New | 2M | New |
| Sold Out Positions | 22 | Sold Out | 659,422 | Sold Out |
| Total Postitions | 221 | -0.9% | 50M | +17.53% |
| Blackrock, Inc. | $16,441.00 | 8.18% | 8.02M | +1M | +17.58% | 2025-09-30 |
| Vanguard Group Inc | $14,280.00 | 7.11% | 6.97M | -193,874 | -2.71% | 2025-09-30 |
| Nuveen, Llc | $4,288.00 | 2.13% | 2.09M | +1M | +120.21% | 2025-09-30 |
| Geode Capital Management, Llc | $4,182.00 | 2.08% | 2.04M | +75,868 | +3.86% | 2025-09-30 |
| State Street Corp | $3,946.00 | 1.96% | 1.93M | +78,175 | +4.23% | 2025-09-30 |
| Two Sigma Investments, Lp | $3,248.00 | 1.62% | 1.58M | +614,229 | +63.33% | 2025-09-30 |
| Renaissance Technologies Llc | $2,619.00 | 1.3% | 1.28M | +389,000 | +43.79% | 2025-09-30 |
| Two Sigma Advisers, Lp | $2,470.00 | 1.23% | 1.21M | +264,400 | +28.11% | 2025-09-30 |
| Morgan Stanley | $2,230.00 | 1.11% | 1.09M | -332,776 | -23.42% | 2025-09-30 |
| Bank Of America Corp /De/ | $2,100.00 | 1.05% | 1.02M | -55,456 | -5.14% | 2025-09-30 |